Clinical Research Studies

Updated:May 3,2018

What is ARAMIS?

Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice. The AHA work in partnership with Duke Clinical Research Institute(DCRI) to promote this Registry. Building upon the existing infrastructure of the nation’s largest ongoing stroke registry (American Heart Association/American Stroke Association Get With The Guidelines-Stroke), the ARAMIS registry will be a multicenter, prospective, observational study of AIS and ICH patient on home anticoagulation therapy.

The ARAMIS registry is fully observational and there is no treatment or management strategies directed by the study protocol. All treatment decisions are at the discretion of the treatment physicians. Read more details about this registry.

What is MaRISS?

Mild and improving stroke symptoms are common, affecting 42% (Smith 2011) to 47% (George 2009) of all patients, and the great majority is not treated with acute recanalization therapy. However, up to one third of these patients are reported to have poor outcomes (Fisher 2010).

A joint endeavor between AHA and the University of Miami, to evaluate treatment options for patients with Mild and Rapidly Improving Stroke Symptoms (MaRISS) was designed to help address a critical knowledge gap: What are the long-term outcomes of patients with a diagnosis of mild stroke? What do they experience after discharge? This will be the first ever large-scale prospective study to evaluate the long-term outcomes for these patients in a standardized manner. Read more details about MaRISS.